Application of silver nanoparticles in the treatment of central serous chorioretinopathy

被引:1
|
作者
Chen, Yao [1 ]
Su, Fanfan [1 ]
Su, Bo [2 ]
机构
[1] Yangtze Univ, Jingzhou Cent Hosp, Clin Med Coll 2, Dept Ophthalmol, Jingzhou 434020, Hubei, Peoples R China
[2] Yangtze Univ, Sch Med, Dept Pathol, Jingzhou 434023, Hubei, Peoples R China
关键词
Silver Nanoparticle; Central Serous Chorioretinopathy; Treatment; COMPOSITE FILM; DNA; NANOCLUSTERS; FLUORESCENCE;
D O I
10.1166/mex.2023.2353
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
The purpose of this study was to explore the therapeutic effect of silver nanoparticles in the treatment of central serous chorioretinopathy (CSC). After the establishment of CSC in New Zealand rabbits (n = 128), the animals were treated with iodized lecithin tablets by gavage (ILT only, n = 64) or ILT gavage followed by injection of silver nanoparticles into the vitreous cavity (SN, n = 64). The sum retinal layer thickness of SN group before gavage was lower than that of ILT group, and the total retinal thickness of SN group after gavage was also lower than that of ILT group. There were interaction effects between groups and time IP: 217 163 11 .10 On Tue 18 Apr 2023 14:08:13 (Fgroup effect = 42.570, Ftime effect = 19.250, Copyright: Finteraction American effect = 2.885,Scien allific <Publishers0.05).Electroretinograms showed lower peak latency in oscillatory potential (OP1, OP2, and OP3) in the SN group than in the ILT group before and after gavage (intergroup effect: F1 = 40.280, F2 = 52.760, F3 =133.700; time effect: F1 =10.330, F2 = 9.082, F3 = 93.760; interaction effects: F1 = 4.204, F2 = 3.059, F3 = 12.260; all P < 0.05). The b-wave amplitudes and total amplitudes were higher in the SN group than in the ILT group before and after gavage (intergroup effect: F1 = 10.540, F2 = 13.270; time effect: F1 = 25.910, F2 = 35.120; interaction effects: F1 = 2.817, F2 = 5.264; all P < 0.05). No significant differences in intraocular pressure were observed, and there were no interaction effects (Fintergroup effect = 0.046, Ftime effect = 0.001, Finteraction effect = 0.027, all P > 0.05). We conclude that silver nanoparticles provide a significant therapeutic effect on CSC in rabbits, ensuring the integrity of retinal morphology, structure, function, and limiting damage to visual function.
引用
收藏
页码:274 / 282
页数:9
相关论文
共 50 条
  • [31] Modified Photodynamic Therapy Treatment of Central Serous Chorioretinopathy
    Putnam, Christopher M.
    Vang, See S.
    OPTOMETRY AND VISION SCIENCE, 2016, 93 (07) : 760 - 771
  • [32] Diagnosed a Patient with Central Serous Chorioretinopathy? Now What?: Management of Central Serous Chorioretinopathy
    Goldhagen B.E.
    Goldhardt R.
    Current Ophthalmology Reports, 2017, 5 (2) : 141 - 148
  • [33] Central serous chorioretinopathy associated with systemic corticosteroid treatment
    Spraul, CW
    Lang, GE
    Lang, GK
    OPHTHALMOLOGE, 1997, 94 (06): : 392 - 396
  • [34] FAMILIAL CENTRAL SEROUS CHORIORETINOPATHY
    van Dijk, Elon H. C.
    Schellevis, Rosa L.
    Breukink, Myrte B.
    Mohabati, Danial
    Dijkman, Greet
    Keunen, Jan E. E.
    Yzer, Suzanne
    Den Hollander, Anneke I.
    Hoyng, Carel B.
    de Jong, Eiko K.
    Boon, Camiel J. F.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2019, 39 (02): : 398 - 407
  • [35] Brachytherapy for Central Serous Chorioretinopathy
    Supriya Arora
    Baldassarre D. Stea
    Russell J. Hamilton
    Jay Chhablani
    Ophthalmology and Therapy, 2022, 11 : 1611 - 1616
  • [36] Traumatic central serous chorioretinopathy
    Steeples, Laura
    Sharma, Vinod
    Mercieca, Karl
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2015, 63 (06) : 536 - 538
  • [37] Central Serous Chorioretinopathy Classification
    Vilela, Manuel
    Mengue, Carolina
    PHARMACEUTICALS, 2021, 14 (01) : 1 - 9
  • [38] Central serous chorioretinopathy: A review
    Bousquet, E.
    Provost, J.
    Torres-Villaros, H.
    Behar-Cohen, F.
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2023, 46 (07): : 791 - 802
  • [39] Masqueraders of central serous chorioretinopathy
    Sahoo, Niroj Kumar
    Singh, Sumit Randhir
    Rajendran, Anand
    Shukla, Dhananjay
    Chhablani, Jay
    SURVEY OF OPHTHALMOLOGY, 2019, 64 (01) : 30 - 44
  • [40] Central serous chorioretinopathy (CSC)
    Baraki, H.
    Feltgen, N.
    Roider, J.
    Hoerauf, H.
    Klatt, C.
    OPHTHALMOLOGE, 2010, 107 (05): : 479 - 492